This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Hoffmann-La Roche Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: David John Carlile: Innovator in Bispecific Antibody Treatments
Introduction
David John Carlile is a notable inventor based in Princes Risborough, GB. He has made significant contributions to the field of medical treatments, particularly in the area of bispecific antibodies. His work focuses on innovative approaches to treating CD20-positive cell proliferative disorders.
Latest Patents
David John Carlile holds a patent for a groundbreaking invention titled "Dosing for combination treatment with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate." This patent addresses the treatment of subjects with CD20-positive cell proliferative disorders, such as non-Hodgkin's lymphomas. The invention specifically involves administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate to effectively treat these disorders. He has 1 patent to his name.
Career Highlights
David John Carlile is associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His role at the company allows him to work on cutting-edge research and development in the field of antibody treatments. His expertise and innovative mindset contribute to the advancement of medical therapies.
Collaborations
Throughout his career, David has collaborated with esteemed colleagues, including Thomas Francis Moore and Katharina Lechner. These collaborations have fostered a productive environment for innovation and research in the field of bispecific antibodies.
Conclusion
David John Carlile is a prominent inventor whose work in bispecific antibody treatments has the potential to significantly impact the treatment of CD20-positive cell proliferative disorders. His contributions to the field are noteworthy and reflect his commitment to advancing medical science.